Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis.

Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.